NCT04533516

Brief Summary

The benefits of inspiratory muscle training(IMT) in patients with chronic obstructive pulmonary disease(COPD) were reported.But in severe COPD patients, benefit from IMT may be limited.There is need for further research in new and complementary modalities to improve IMT efficiency in severe COPD patients.Manual therapy(MT) additional over IMT may be such a new approach that has not yet been investigated in COPD. Aims: To investigate effects of MT additional over IMT on functional capacity,respiratory muscle strength,pulmonary function,dyspnea, fatigue and quality of life in severe COPD patients. Methods: It was a prospective single-blind randomized trial. 40 patients with COPD in Global Initiative for Chronic Obstructive Lung Disease(GOLD) stage III-IV were included. Patients were randomly assigned to receive either MT additional over IMT at 40% of maximal inspiratory pressure(MIP)(n= 20) or only IMT(n= 20) for 12 weeks. MT group received MT during 12 weeks for 40 minutes additional to IMT. Pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, functional capacity using six minute walk test, dyspnea using Modified Medical Research Council(MMRC) dyspnea scale, fatigue using fatigue severity scale and quality of life using St. George's Respiratory Questionnaire(SGRQ) were evaluated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2020

Completed
4 days until next milestone

Study Start

First participant enrolled

August 29, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 31, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 5, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 12, 2021

Completed
Last Updated

July 8, 2021

Status Verified

July 1, 2021

Enrollment Period

4 months

First QC Date

August 25, 2020

Last Update Submit

July 2, 2021

Conditions

Keywords

copdmanual therapyinspiratory muscle therapy

Outcome Measures

Primary Outcomes (6)

  • Pulmonary Function Test

    Before the pulmonary function test, all subjects rested to avoid fatigue. The lung function test including forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and vital capacity (VC) was performed in a seated position using a portable spirometer according to the American Thoracic Society guidelines.

    12 weeks

  • respiratory muscle strength

    For respiratory muscle strength, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) were evaluated using an electronic pressure transducer. MIP was measured at residual volume, and MEP was measured from total lung capacity.

    12 weeks

  • 6 minute walk test

    6 minute walk test (6MWT) was applied to measure exercise capacity. The patient's heart rate, breathing frequency, and oxygen saturation were monitored with the pulse oximeter, and the values were recorded before and after the test. The distance was expressed both as metres.

    12 weeks

  • Dyspnea perception

    Dyspnea perception was assessed using the modified Medical Research Council (MMRC) dyspnea scale, Levels of dyspnea are graded 0 (absence of dyspnea during strenuous exercise), to 4 (dyspnea during daily activities).

    12 weeks

  • Fatigue perception

    Fatigue perception was assessed with Turkish version of Fatigue Severity Scale. A high score indicates increased fatigue intensity and the maximum score of the scale is 63.

    12 weeks

  • St.George Respiratory Questionnaire

    Quality of life was measured using the Turkish version of St.George Respiratory Questionnaire (SGRQ). It is a specific quality of life questionnaire for respiratory diseases. SGRQ consists of three subscale and 50 items; symptoms (8 items), activities (16 items), effects of the disease (26 items). Each subscale is scored ranging from 0 to 100 points. High scores indicate that worsened the quality of life.

    12 weeks

Study Arms (2)

Manual Therapy additional over Inspiratory muscle training

EXPERIMENTAL

Participants receive manual therapy protocol session three times a week for 12 weeks. The manual therapy protocol session lasts 30 minutes and included of the following manual therapy techniques: suboccipital decompression, gliding of the cervical vertebral articulations in the anterior/posterior direction, myofascial release of sternocleidomastoid and trapezius muscles, gliding of sternoclavicular joint in the anterior/posterior direction, myofascial release of intercostal muscles and paravertebral muscles, diaphragmatic release, rib raising, mobilization of scapulothoracic joint, and gliding of the thoracic vertebral articulations in the anterior/posterior direction. And all participants receive inspiratory muscle training.

Other: Manual therapy technicsOther: Inspiratory Muscle Training

Inspiratory Muscle Training

ACTIVE COMPARATOR

Participants receive only inspiratory muscle training by using Threshold Inspiratory Muscle Training device. Training load is 40% of the measured maximum inspiratory pressure, weekly. Participants receive inspiratory muscle training session for 30 min-per day, 7 days per week, for 12 weeks.

Other: Inspiratory Muscle Training

Interventions

Manual therapy technics

Manual Therapy additional over Inspiratory muscle training

Inspiratory Muscle Training

Inspiratory Muscle TrainingManual Therapy additional over Inspiratory muscle training

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of chronic obstructive pulmonary disease
  • Being clinically stable
  • Having FEV1/FVC ratio of ≤ 50% of the predicted value after bronchodilator drugs.

You may not qualify if:

  • Having an acute bronchitis,
  • Having a pneumonia,
  • Having an exacerbation of COPD,
  • Having thoracic spinal scoliosis,
  • Having substantial chest wall deformity, or acute rib or vertebral fracture.
  • Unable to perform the pulmonary function test because of cognitive or physical impairments.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

İstinye University

Istanbul, 34010, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Muscle WeaknessPulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease Attributes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physiotherapist, PhD, Associate Professor

Study Record Dates

First Submitted

August 25, 2020

First Posted

August 31, 2020

Study Start

August 29, 2020

Primary Completion

January 5, 2021

Study Completion

April 12, 2021

Last Updated

July 8, 2021

Record last verified: 2021-07

Locations